The value of tools to assess pulmonary arterial hypertension

H. Gupta*,#, G. Ghimire* and R. Naeije*

ABSTRACT: Pulmonary hypertension is a common but complex clinical problem. When suspected in an appropriate clinical setting or detected incidentally, an array of investigative tools are employed with an intent to confirm the diagnosis, define aetiology, evaluate the functional and haemodynamic impairment, define treatment options, monitor the therapy, and establish long-term prognosis. However, no single tool provides comprehensive information that encompasses the aforementioned aims. Therefore, judicious use of these tools is of paramount importance, in order to maximise outcome and cost-effectiveness, while minimising risks and redundancies. Furthermore, a number of promising tools and techniques are emerging rapidly in the arena of pulmonary hypertension. These tools augment our understanding of pathophysiology and natural history of pulmonary hypertension. There is, therefore, increasing need for validating these emerging paradigms in multicentre trials. In this review, we focus on the tools commonly used to evaluate pulmonary arterial hypertension and also define some of the new approaches to pulmonary arterial hypertension.

KEYWORDS: Cardiac magnetic resonance imaging, echocardiography, pulmonary arterial hypertension, right heart catheterisation, right ventricular strain

Pulmonary hypertension (PH) is defined as an increase in mean pulmonary arterial pressure (P¯pa) ≥25 mmHg at rest on right heart catheterisation (RHC) [1]. The clinical classification of PH has evolved through a series of changes since its initial proposal in 1973 at the first international conference on primary PH, endorsed by the World Health Organization [2]. The current clinical classification groups PH into five diagnostic categories [3]: group 1: pulmonary arterial hypertension (PAH); group 2: PH with left-sided heart disease; group 3: PH associated with lung disease and/or hypoxaemia; group 4: PH due to chronic thrombotic and/or embolic disease (CTEPH); and group 5: miscellaneous group.

The clinical evaluation of suspected PH entails investigations that are intended to confirm the diagnosis, define aetiology, evaluate the functional and haemodynamic impairment, define treatment selection and monitor the therapy along with long-term prognostication. In this review, we will focus on the tools commonly used to evaluate PAH and also define some of the new approaches to PAH.

Since the diagnosis of PAH involves excluding all other reasonable possibilities, the diagnostic algorithm generally starts with the identification of the more common clinical groups of PH (group 2, left heart disease and group 3, lung diseases), then distinguish group 4, CTEPH, and finally make the diagnosis and recognise the different types in group 1, PAH, and the rarer conditions in group 5. However, an abnormality of one test does not preclude that another abnormality may be contributing or predominant. Contingent tests are recommended to elucidate or confirm results taking into account appropriate clinical context.

TESTS TO CONFIRM THE DIAGNOSIS OF PAH

Right heart catheterisation

RHC is the current reference standard for the diagnosis and assessment of the severity of the haemodynamic impairment in PAH [4, 5]. The utility of RHC depends on the accuracy and completeness of the data obtained. Essential components of RHC are accurate measurements of right atrial pressure (Pr), right ventricular pressure, systolic Ppa (Ppa,syst), diastolic Ppa, Ppa and pulmonary capillary wedge pressure (Ppcw), along with measurements of oxygen saturation of blood sampled from the superior/inferior vena cava, pulmonary artery and systemic arterial circulation. The influence of intrathoracic pressure on
intracardiac pressure measurement is mitigated by recording the measurement at end-expiration when intrathoracic pressure is near zero [6]. Measurements at end-expiration were introduced in the 1980s. Earlier RHC studies averaged pressures over the respiratory cycle. The rationale for measurements at end-expiration is rather that it minimises the influence of lung volume on pulmonary vascular resistance (PVR) [7]. However, in the presence of increased respiratory pressure and volume swings, like in decompensated chronic obstructive pulmonary disease or at high levels of exercise, averaging pressures over the respiratory cycle is preferable. The Fick method remains the gold standard for estimating cardiac output (CO), provided it is used in strictly steady-state conditions, which is rarely the case [8]. In clinical practice, CO based on thermodilution techniques is frequently obtained. Generally, CO measured in triplicate by thermodilution suffices if the values are consistent, provided there is no significant systemic-to-pulmonary shunting, in which case the Fick method is mandatory. Contrary to the general conception, thermodilution CO is not affected by tricuspid regurgitation [9, 10].

$P_{pcw}$, a surrogate measurement for left atrial pressure in absence of pulmonary vein obstruction, is required for differentiating group 1 from group 2 categories of PH. To measure the $P_{pcw}$, the pulmonary artery catheter tip must be located in a lung segment where pulmonary vein pressure exceeds the alveolar pressure (physiologic zone 3) [11]. In a supine patient during RHC, a major portion of the lung is in zone 3 and, therefore, the catheter tip is naturally directed to this zone. Evidence of distinct A and V waves on $P_{pcw}$ tracings indicates the catheter tip being in zone 3. Conditions such as hypovolaemia, advanced parenchymal lung disease or positive pressure ventilation will render the alveolar pressure in excess of the pulmonary vein pressure, thus creating zones 1 or 2. In these instances, $P_{pcw}$ becomes a measure of alveolar pressure rather than left atrial pressure ($P_{la}$). The optimal position of the wedging catheter tip can be further ascertained by fluoroscopy and checking the pulmonary vein oxygen saturation, which should be equal to systemic arterial oxygen saturation. If the wedge pressure tracing is suboptimal, a measurement of left ventricle end-diastolic pressure should be obtained by left heart catheterisation.

PVR is obtained by dividing the transpulmonary gradient ($P_{pa} - P_{pcw}$) by the CO, and is considered a robust diagnostic criterion for PAH because it reflects the influence of transpulmonary gradient and CO and is only elevated if the vascular obstruction occurs within the precapillary pulmonary circulation [5]. PVR distinguishes passive PH (elevated $P_{pa}$, normal PVR) from PH caused by pulmonary vascular disease (elevated $P_{pa}$, elevated PVR). The conventional definition of PAH used in clinical studies includes a $P_{pa}$ of $\geq 25$ mmHg at rest in the setting of a normal $P_{pcw}$ of $\leq 15$ mmHg or less with a PVR $>3$ Wood units. However, potential exceptions to this definition will involve certain conditions with high flow rates, for instance uncorrected congenital heart disease, sickle cell disease and portopulmonary hypertension. Despite the pivotal role of RHC in evaluation of PAH, the technique has some limitations. Even at experienced centres, RHC procedures are associated with a morbidity of 1.1% and a mortality of 0.055% [12]. The haemodynamic variables obtained at RHC are susceptible to phasic fluctuation due to the respiratory cycle or artifactual fluctuations due to hyperventilation and valsalva manoeuvre. Furthermore, RHC is performed under artificial filling conditions, e.g. at rest and after overnight fasting, which may not correspond to the true pulmonary haemodynamic conditions during patients’ daily lives. This technique is also susceptible to common errors in zero levelling, over-damping (insufficient flushing) or under-damping (over-flushing) pressure curves and, in general, the insufficient frequency responses of fluid-filled catheters. The advent of implantable haemodynamic monitors providing continuous haemodynamic data may mitigate some of these limitations and may be useful in monitoring the therapy of PAH, although the intermediate to long-term accuracy of these estimates are not yet defined [13, 14].

Vasodilator challenge

Pulmonary vasodilatation testing is performed to evaluate the reversible component of PAH. It helps identify patients with better prognosis and patients who could potentially benefit from treatment with calcium channel blockers (CCBs) [15–17]. Acute vasodilator testing is most commonly performed using inhaled nitric oxide [18], intravenous epoprostenol [19] or intravenous adenosine [20]. A positive acute response was, until recently, defined as a reduction of both $P_{pa}$ and PVR of at least 20% relative to baseline values [21]. However, recent consensus defines a favourable response as a fall in $P_{pa}$ $\geq 10$ mmHg to a $P_{pa} \leq 40$ mmHg, with an unchanged or increased CO [22]. Using this criterion, only $\sim$10% of patients with idiopathic PAH will be regarded as acute responders. About 50% of acutely responding idiopathic PAH patients respond long-term to CCBs [17]. While sensitivity of acute vasodilator test is insufficient to identify all patients who may be responsive to long-term CCB therapy, it is sufficiently specific to identify patients who have a high likelihood of benefiting from chronic CCB therapy. Caution should be exercised while performing this test as these agents could lead to an acute increase in right-to-left blood flow and, potentially, overload a poorly compliant left ventricle. Their use in patients with elevated left ventricular filling pressures can cause acute pulmonary oedema [23]. In addition, a minority of patients with PAH will have significant peripheral vasodilatation leading to hypotension (negative responders).

Echocardiography

Doppler echocardiography is the pivotal screening test for noninvasive assessment of suspected PAH and provides several variables which correlate closely with right heart haemodynamics, including $P_{pa}$ (figs 1 and 2). The $P_{pa,syst}$ is derived from the tricuspid insufficiency peak gradient (TIPG) using the equation: $P_{pa,syst} = TIPG + estimated P_{ra}$. $P_{ra}$ can be estimated based on the diameter and respiratory variation of the inferior vena cava, although often a fixed value of 5 or 10 mmHg is assumed. The TIPG is derived from tricuspid jet velocity (TJV) using the simplified Bernoulli equation: $TIPG = 4 \times (TJV)^2$. In 10–25% of patients being evaluated for possible PH, the spectral Doppler profile of tricuspid insufficiency is too weak or insufficient to measure the pressure gradient across the tricuspid valve [24, 25]. The spectral tricuspid regurgitation signal can be augmented by use of contrast echocardiography (e.g. agitated saline or encapsulated microbubble contrast agents), allowing proper measurement of peak TJV.
Theoretically, the $P_{pa}$ can be derived from $P_{pa,syst}$ by using the equation: $P_{pa} = 0.61 \times P_{pa,syst} + 2 \text{ mmHg}$ [26]. However, despite strong correlation between TJV and TIPG, the Doppler-derived $P_{pa,syst}$ may be inaccurate in individual patients. For example, in the ItinerAIR study that comprised of 599 patients with scleroderma, if PH is defined on the basis of Doppler-derived TJV of 3.0 m s$^{-1}$ or TJV of 2.5–3.0 m s$^{-1}$ with dyspnoea, it corresponded to a false-positive rate of 45% when compared with RHC [27].

Currently, mild PH is arbitrarily defined as TJV of 2.8–3.4 m s$^{-1}$, which corresponds to TIPG 31–46 mmHg and to $P_{pa}$ 36–51 mmHg, if a fixed $P_{ra}$ estimate of 5 mmHg is used [28]. This was endorsed by the 2009 European Society of Cardiology task force guidelines for the diagnosis and treatment of PH (table 1) [4].

A major problem of using echocardiography to evaluate the pulmonary circulation as it is practised in many centres is the exclusive reliance on the maximal velocity of tricuspid regurgitation for the calculation of pulmonary artery pressures. Since $P_{pa}$ is a flow-dependent variable, it is important to couple it with a measurement of CO (Q). This can be measured from the left ventricular outflow tract (LVOT) diameter and velocity integral (VTI) multiplied by cardiac frequency (fc) [29, 30]; $Q = (0.785 \times \text{VTI}_{LVOT}^2) \times \text{VTI}_{LVOT} \times \text{fc}$. For the direct calculation of PVR, it is also necessary to know $P_{ra}$ or $P_{pcw}$. This can be calculated from the ratio of transmitral Doppler and mitral tissue Doppler E and E’ waves [31]; $P_{ra}$ or $P_{pcw}$ (mmHg) = $1.24 \times E' / E$ + 1.9. $P_{pa}$ can be calculated by the equation [32]: $P_{pa}$ (mmHg) = $0.61 \times P_{pa,syst} + 2$. It is also possible to calculate pulmonary flow at the right ventricular outflow tract (RVOT) by measuring VTI$_{RVOT}$, but the calculation of volume flow produces a less stable measurement than sampled from the LVOT. VTI$_{RVOT}$ and tricuspid regurgitation flows can be combined to calculate PVR [33] as follows: PVR (in Wood units) = 0.16 + 10 × (VTI/VTI$_{RVOT}$), or using a simplified equation PVR (in Wood units) = 10 × (VTI/VTI$_{RVOT}$). If TJV/VTI$_{RVOT}$ <0.2, PVR values are likely to be normal, even in the presence of Doppler evidence of increased $P_{pa,syst}$ [33]. Another useful independent method to estimate $P_{pa}$ is based on the pulsed Doppler measurement of the acceleration time (AT) of pulmonary flow (sampled at the RVOT) [34, 35]: $\log_{10} P_{pa} = -0.0068 (AT) + 2.1$; or $P_{pa}$ (mmHg) = $79 - (0.45 \times AT)$. Given the importance of a reliable estimate of $P_{pa}$ for the diagnosis of PH, and given the uncertainties...
encountered with the sampling of good quality TJV or pulmonary insufficiency, it is surprising that internal controls based on AT are so uncommonly reported. However, there has been less validation of this method against invasive measurements than reported on the basis of TJV. Accurate estimates of $P_{pa}$ are less reliable when AT exceeds 100 ms, the lower limit of normal, and the measurement may need a correction for ejection time at high heart rates [36]. However, there are data suggesting that AT may be more sensitive than tricuspid regurgitation to early or late pulmonary vasculopathy [37], which may be due to its sensitivity to changes in pulmonary vascular impedance more than PVR. The advantage of the measurement of $P_{pa}$ on the basis of the AT of pulmonary flow is in a quasi 100% recovery of good quality signals, independently on the level of $P_{pa}$. In addition to AT, the shape of the flow wave is of interest, as PH is associated with a deceleration of flow in late or in mid systole (notching). A decreased time to notching has been reported to be of poor prognosis, and to identify proximal obstruction in patients with CTEPH [38]. Finally, as recently emphasised in the guidelines [4], estimations of $P_{pa}$ or PVR have to be integrated in the context of a complete echocardiographic examination of the heart. An increased TJV in the presence of a completely normal right ventricular size and function does not require further exploration.

**Cardiac magnetic resonance**

*Estimation of right ventricular systolic pressure*

Cardiac magnetic resonance imaging (cMRI) (fig. 3) is generally considered a noninvasive reference standard for evaluating biventricular dimensions, geometry and function [40, 41]. The configuration and curvature of the septum is a function of transseptal pressure gradient [42, 43], whereas transmural pressure gradient determines the left ventricular free wall curvature [44].
Patients with PH may have a substantially reduced trans-septal pressure gradient, which may lead to the frequently observed flattening (or bowing) of the intraventricular septum (IVS) [42]. According to the law of Laplace, wall stress is proportional to the rate of pressure rise (dP) divided by the product of wall thickness and curvature [45]. This relationship may be independently applied to derive wall stress information across the IVS and the free wall. In the absence of asymmetric hypertrophy, the wall stress in the IVS and in the free wall may be assumed to be similar; thus, any change in the dP ratio (i.e. trans-septal pressure gradient divided by effective distending transmural pressure) should affect the curvature ratio $R_C$ (ratio of curvature of IVS and curvature of left ventricular free wall) proportionally. Using echocardiography, RESNER et al. [46] proposed an equation to obtain right ventricular systolic pressure ($P_{Rv,syst}$) from systolic blood pressure (SBP):

$$P_{Rv,syst} = SBP \times \frac{1}{[1 - (R_C/1.03)]}.$$  

Using cMRI and RHC as reference measures this equation was validated with a good correlation ($r=0.85$) [47].

Sustained increase in right ventricular afterload in patients with PAH leads to alteration in right ventricle morphology; the change mirrors the severity of $P_{pa}$. Using this concept, ventricular mass index (VMI), which is the ratio between magnetic resonance imaging (MRI)-derived right ventricle mass and left ventricle mass, were obtained in patients with suspected PAH and correlated with echocardiographic and invasive haemodynamic variables [48]. The correlation between VMI

### TABLE 1 Definition of pulmonary hypertension (PH)

| Echocardiographic diagnosis: PH unlikely | TJV ≤ 2.8 m·s$^{-1}$, $P_{pa,syst}$ ≤ 36 mmHg, and no additional echocardiographic variables suggestive of PH |
|----------------------------------------|---------------------------------------------------------------------------------------------------|
| Echocardiographic diagnosis: PH possible | TJV ≤ 2.8 m·s$^{-1}$, $P_{pa,syst}$ ≤ 36 mmHg, but presence of additional echocardiographic variables suggestive of PH |
|                                       | TJV ≥ 2.8–3.4 m·s$^{-1}$, $P_{pa,syst}$ 37–50 mmHg with/without additional echocardiographic variables suggestive of PH |
| Echocardiographic diagnosis: PH likely | TJV > 3.4 m·s$^{-1}$, $P_{pa,syst}$ > 50 mmHg, with/without additional echocardiographic variables suggestive of PH |

TJV: tricuspid jet velocity; $P_{pa,syst}$: pulmonary artery systolic pressure. Reproduced from [4], with permission from the publisher.

![FIGURE 3](image-url). Cardiac magnetic resonance imaging (MRI) evaluation of cardiac remodelling in pulmonary arterial hypertension (PAH). a) Short axis view of cine-MRI frame at systole and b) corresponding tagged MRI images are shown. c) Three-dimensional strain maps from normal (NL) compared with PAH subjects are shown in various phases of the cardiac cycle. Adapted from [39].

Reproduced from [4], with permission from the publisher.
and RHC-derived $P_{pa}$ was stronger than the correlation using echocardiographically derived $P_{pa}$. Confidence intervals were also narrower for VMI than those for echocardiography. The sensitivity and specificity of VMI as a predictor of $P_{pa}$ is lower than in a matched group of volunteers. Pulmonary artery distensibility were found to be significantly lower than in the pulmonary arteries of PAH patients, with retrograde flow proportional to pulmonary resistance and inversely proportional to flow and minimum pulmonary artery area emerged as useful parameters. Other parameters such as AT and ejection time can also be obtained from PC-MRI dataset.

When these PC-MRI parameters were compared with RHC-derived parameters, average velocity of pulmonary artery flow and minimum pulmonary artery area emerged as useful parameters for the evaluation of PAH (area under receiver operating characteristic curve 0.90 for average velocity and 0.95 for minimum pulmonary artery area) [49]. Use of velocity-encoded cine-MRI has revealed reduced peak systolic velocity and greater post-systolic retrograde flow in the pulmonary arteries of PAH patients, with retrograde flow proportional to pulmonary resistance and inversely proportional to flow volume [50]. In a study of 25 patients with PAH, mean pulmonary artery peak flow velocity, pulmonary artery blood flow and pulmonary artery distensibility were found to be significantly lower than in a matched group of volunteers ($p=0.002$, $p=0.002$ and $p=0.008$, respectively) [51].

Laffon et al. [52] have proposed a computerised algorithm for estimating $P_{pa}$ based on cMRI-derived indices (e.g. pulmonary artery cross-sectional area and blood flow velocity) that are weighted using patient-specific biophysical parameters (e.g. height, weight and heart rate). When this algorithm was applied to a series of 31 patients undergoing RHC, the calculated $P_{pa}$ based on MRI-derived parameters correlated strongly with catheterisation-derived values ($r=0.92$). However, in a subsequent study that assessed 44 patients with established PAH, a poor correlation was found between catheterisation-derived $P_{pa}$ and five different MRI-derived measures [53], including pulmonary vascular index, AT (defined as time from onset of pulmonary artery forward flow to maximum velocity), the ratio between AT and ejection time, and the algorithm proposed by Laffon et al. [52] discussed previously. The only significant correlation between catheterisation-based $P_{pa}$ and MRI-based measures was for ventricular mass index ($r=0.56$, $p<0.001$).

**Computed tomography scan**

Topographic manifestations of PAH on cardiopulmonary computed tomography (CT) are: increase in the ratio of the widest short axis diameter of the right ventricle to the left ventricle on axial CT, flattening and eventual convexity of the IVS with progressive right ventricle enlargement, and reflux of contrast from the right atrium into the inferior vena cava [54]. It has been shown that a ratio of the mean pulmonary artery to ascending aorta size >1 is indicative of PAH [55]. In addition, the coronary sinus is dilated and correlates to pulmonary pressures determined by RHC [56]. CT scanning of the lungs can also provide morphological hints to help rule out other disorders, such as CTEPH and luminal and mural thrombi. Limitations of the use of CT in PAH diagnosis include: CT does not provide pulmonary pressure; the absence of changes in the pulmonary artery does not eliminate the possibility that a patient has PAH; pulmonary artery and ascending aorta diameters may change with body size; dilation of the main pulmonary artery can occur with other pulmonary disorders, such as pulmonary fibrosis; and size estimates of the pulmonary artery may require more than one axial dimension [54].

**Tests to prognosticate PAH**

**Right heart catheterisation**

The prognostic significance of the haemodynamic variables to predict outcomes in PAH was illustrated in the pre-epoprostenol era by the National Institutes of Health registry [57]. On univariate analysis, increased $P_{pa}$ (OR 1.16, 95% CI 1.05–1.28), increased $P_{pa}$ (OR 1.99, 95% CI 1.47–2.69), and decreased cardiac index (CI) (OR 0.62, 95% CI 0.46–0.82) were associated with increased risk of death. Baseline $P_{pa}>20$ mmHg carries a 6-month mortality rate of almost 100% without treatment. These variables were also robust predictors in multivariate analysis. Using these three variables, a regression equation was formulated to predict the probability of survival ($P$) in 1, 2 or 3 yrs ($t$) after diagnosis: $P(t)=H(t)A^{x,y,z}$, where $H(t)=0.88 - 0.14t + 0.01t^2$, $A^{x,y,z}=e^{0.007325x + 0.0526y - 0.3275z}$, $t =$ years, $x = P_{pa}$ (mmHg), $y = P_{pa}$ (mmHg), and $z = CI$ (L min$^{-1}$ m$^{-2}$). This equation was subsequently validated [58] but its utility in the post-epoprostenol era has not been established. Some evidence supports that the baseline haemodynamic variables may confer less prognostic information in epoprostenol-treated patients [59]. The $P_{pa}$ may lose its prognostic significance along the natural course of the PAH as the failing right ventricle attenuates the $P_{pa}$ [58]. Positive response to acute vasodilator testing portends excellent prognosis with 95% survival at 5 yrs [17, 21]. However, these prognostic indices were derived from patients with idiopathic PAH and may not be directly applicable to PAH related to connective tissue disorders, congenital systemic-to-pulmonary shunts, HIV infection, or portal-pulmonary hypertension. Important information about predicting survival in PAH has been provided by a French registry and the REVEAL registry. Multivariable analysis of 354 consecutive adult patients with idiopathic, familial or anorexigen-associated PAH (56 incident and 298 prevalent cases) in the French registry showed female sex, greater 6-min walk distance and higher CO are jointly significantly associated with improved survival [60]. Analysis of 2,716 patients in the REVEAL registry, which is a multicentre, observational, US-based registry, have demonstrated additional key predictors of survival and helped generate a clinically useful prognostic equation [61].

**Echocardiography**

While echocardiography is pivotal in the PAH assessment paradigm as an early screening tool, the prognostic information of the echocardiographic variables in PAH is limited due to relatively small series. Those indices with the best prognostic significance identified by multivariate analysis are
pericardial effusion [61–63], indexed right atrium area [63], left ventricular eccentricity index [63] and the right ventricular Doppler index [64, 65]. Estimated $P_{pa,syst}$ derived from TJV has been shown to be non-prognostic [63]. The tricuspid annular plane systolic excursion (TAPSE), which measures the systolic displacement of the tricuspid annulus toward the right ventricle apex, has been shown to correlate closely with right ventricular ejection fraction [66]. In PH (majority PAH), TAPSE <1.5 cm is associated with clinical deterioration and worst prognosis and TAPSE >2.0 cm indicates better prognosis [67]. Similarly, TAPSE of ≥1.8 cm was associated with survival estimates of 94% and 88% at 1 and 2 yrs, respectively, and survival estimates of 60% and 50%, respectively, in subjects with a TAPSE ≤1.8 cm [67].

The myocardial performance index (Tei index or right ventricular Doppler index) is a more physiological index and is calculated as the ratio between the sum of the times of the isovolumic periods and the ejection time for the right ventricle
calculated as the ratio between the sum of the times of the
cyclic Doppler index [64, 65]. Estimated $P_{pa,syst}$ derived from TJV has been shown to be non-prognostic [63].

Cardiovascular magnetic resonance
cMRI provides morphological and functional parameters with high accuracy, reproducibility and low inter-study variability [68]; these characteristics render it an attractive prognostication and follow-up tool. In a study of 64 patients with idiopathic PAH, baseline right ventricular stroke volume index >25 mL m$^{-2}$, right ventricular end-diastolic volume <84 mL m$^{-2}$, and left ventricular end-diastolic volume (LVEDV) >40 mL m$^{-2}$ were predictive of survival [69]. In a multivariate analysis, only 6-min walk test (6MWT) added incremental prognostic information over these three cMRI variables. In addition, a further decrease in stroke volume, progressive right ventricular dilatation, and further decrease in LVEDV at 1-yr follow-up were the strongest predictors of mortality in this study group [69]. Pulmonary artery distensibility, as measured by relative cross-sectional area change by cMRI was predictive of survival in a cohort of 86 PAH patients. Those with a relative cross-sectional area change of <16% had a greater mortality than those with a value >16% [70].

Exercise tolerance
6MWT is a well standardised and reproducible test, which provides quantitative measures of exercise tolerance in terms of distance walked, dyspnoea on exertion (Borg scale) and finger oxygen saturation. Walking distances of <332 m [71] or <250 m [59] and oxygen desaturation >10% [72] indicate impaired prognosis in PAH. In the pivotal epoprostenol idiopathic PAH trial, performance in the unencouraged 6MWT was found to be an independent predictor of survival [73], leading to the acceptance of this test by the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products as an primary end-point for the evaluation of treatment effects in PAH in clinical trials.

Maximal oxygen consumption determined by progressive exercise testing with cycle ergometry has also been found to be an independent predictor of survival in idiopathic PAH. Following multivariate analysis of clinical, haemodynamic and exercise parameters in 70 of the 86 patients that were able to complete the exercise protocol, peak oxygen uptake (10.4 mL·kg$^{-1}$·min$^{-1}$) and peak systolic arterial pressure during exercise (120 mmHg) independently predicted a worse prognosis in idiopathic PAH [74]. In addition, in idiopathic PAH patients treated with epoprostenol, the exercise duration has also been shown to be predictive of survival [75]. While the results of both methods do correlate in PAH, cardiopulmonary exercise test (CPET) failed to confirm improvements observed with 6MWT in randomised controlled trials [76, 77]. This discrepancy has been attributed to lack of standardisation and insufficient expertise in performing CPET [78].

Biomarkers
Both atrial natriuretic peptide and brain natriuretic peptide (BNP) are released from myocardium in response to wall stress and share similar physiological properties inducing vaso-dilatation and natriuresis. In a PAH study, baseline plasma BNP was an independent predictor of mortality after multivariate analysis, with supramedian level of baseline BNP of $\geq 150$ pg·mL$^{-1}$ associated with significantly lower survival rate than those with an inframedian level of $\leq 150$ pg·mL$^{-1}$. After 3 months of target therapy, a supramedian value $\geq 180$ pg·mL$^{-1}$ was associated with strikingly worse survival [79]. Similarly, N-terminal pro-BNP (NT-proBNP), a high molecular precursor of BNP, is related to alteration in right ventricle morphology and dysfunction as assessed by echocardiography and RHC in PH patients with baseline serum NT-proBNP levels of $\geq 1,400$ pg·mL$^{-1}$ portending poor long-term prognosis [80]. Detectable cardiac troponin T also confers a poor prognosis, potentially due to the effect of right ventricle strain and ischaemia [81]. Elevated uric acid levels in PAH are also associated with severity of New York Heart Association (NYHA) functional class and impaired CO [82]. Furthermore, increased uric acid levels are independently associated with long-term mortality of patients with PAH [82].

TESTS FOR TREATMENT SELECTION AND MONITORING DISEASE
Conventionally, RHC with appropriate clinical context has been used to diagnose and determine initial treatment selection. However, there is no universally accepted consensus about the timing and frequency of subsequent RHCs. Pragmatically, most centres perform RHC when there is a change in clinical status, when change in treatment is considered, and 3–6 months after initiating new treatments, so as to ensure that the pulmonary haemodynamics are in the desired range. Currently, RHC and echocardiography are the primary tools used in the diagnosis and monitoring of PAH. However, cMRI has already superseded echocardiography as a reference standard for the noninvasive evaluation of right ventricle morphology and function that is integral to PAH management. Increasing evidence suggests that cMRI can be used effectively to guide and monitor PAH therapy [69, 83].

Figure 4 summarises various tools and parameters that are used for prognosticating and treatment selection in PAH. Interestingly, most of the predictors in PAH relate to the function of the right ventricle rather than the severity of the elevation in $P_{pa}$. 
Correlates better to CO than Ppa. Moreover, NYHA functional class and exercise capacity measures the efficiency of ventricular–vascular haemodynamic function, Ea is a surrogate of vascular function, and their ratio, effective elastance (Ea) [86], Ees is an index of ventricular function in isolation without taking into consideration the pulmonary vascular function ignores the important interactions [87, 88]. When the ventricle and the vasculature are efficiently coupled, minimal energy is wasted engendering the pulse pressure and maximal energy is transmitted in the mean pressure [89]. In this case, the ventricle operates at a maximum efficiency and submaximal stroke work such that Ees/Ea >1.5. In contrast, for a failing ventricle or high impedance vasculature, energy may be dissipated through a variety of mechanisms. In these cases, Ees/Ea <1 and ventricular–vascular uncoupling occurs [90, 91]. Pressure–volume loops at different levels of preload are required for measuring Ees, which can be difficult to achieve clinically. Single-beat methods have been developed to enable calculation of Ees and Ea from only right ventricle and Ppa waveforms [92]. The single-beat method to measure right ventricle–arterial coupling has been applied at the bedside [93, 94]. However, the application of the method needs expertise and specialised training. It is currently being refined and automated to make it easier to use in clinical practice and to base it on noninvasive measurements, i.e. recalibration of a right ventricle pressure curve from tricuspid regurgitation jet velocity and a relative change in right ventricle volume from pulmonary flow measurements.

To address aspects related to pulmonary impedance, the pulmonary vascular impedance spectrum (PVZ) has been proposed as a comprehensive measure of pulmonary vascular function obtained from spectral analysis of Ppa and flow waves [95]. The PVZ spectrum is expressed as a pressure/flow ratio and a phase angle, both of which are expressed as a function of frequency. Evidence suggests that it is a superior predictor of right ventricular failure in PAH compared to PVR [96]. Although
| Therapy | Patients | Conventional end-points | Surrogate end-points |
|---------|----------|-------------------------|----------------------|
| **cMRI** |          |                         |                      |
| Epoprostenol [83] | 11 PAH | ↑ 6MWD | ↑ RVSV | ↓ PVR | ↑ CO | ↔ RVEDV | ↔ RV mass | ↔ \( P_{pa} \) |
| Bosentan [116] | 16 PAH | ↑ 6MWD | ↔ RVEF | | | | | |
| Bosentan/sildenafil [117] | 26 PAH (IPAH and CTD-APAH) | ↑ 6MWD | ↓ RV mass | ↑ CI | | | | |
| Bosentan and sildenafil [118] | 9 IPAH | ↑ 6MWD | ↑ RVSV | | | | | |
| | 3 CTD-APAH | ↑ CI | | | | | | |
| | 2 CHD-APAH | | | | | | | |
| | 1 HIV-APAH | | | | | | | |
| Ambisertan [119] | 11 IPAH | ↑ 6MWD | ↑ RVSV | ↓ PVR | | | | |
| | 1 drug-induced PAH | ↓ 6MWD | | | | | | |
| Sildenafil [120] | 4 IPAH | ↑ 6MWD | ↓ RV mass | ↓ PVR | | | | |
| | 1 CHD-APAH | | | | | | | |
| **Echocardiography** |          |                         |                      |
| Epoprostenol [121] | 9 IPAH | ↓ NYHA FC | ↓ RV dilatation | | | | | |
| | 1 CTD-APAH | | | | | | | |
| | 2 CHD-APAH | | | | | | | |
| | 4 PPH | | | | | | | |
| | 1 CTEPH | | | | | | | |
| | 2 sarcoid | | | | | | | |
| | 1 IPF | | | | | | | |
| Bosentan [122] | 48 IPAH | ↑ 6MWD | ↑ CI | ↓ LVEDD filling velocity | ↑ LVED area | ↓ LVED | ↓ RVES area | ↓ RV-LV diastolic areas | Pericardial effusion score | ↓ RVSP | ↔ \( P_{pa} \) | ↔ RVSP | ↔ Tei index |
| | 7 CTD-APAH | ↓ NYHA FC | | | | | | | |
| | 1 other PAH | | | | | | | |
| Bosentan [123] | 13 CTD-APAH | ↑ 6MWD | ↓ RVSP | | | | | | | |
| Sildenafil [124] | 11 PAH | ↔ NYHA FC | ↔ RVSP | ↔ 6MWD | ↔ Tei index | | | | | | | |
| | 1 CTEPH | | | | | | | |
| | 1 PPH | | | | | | | |
| Epoprostenol/treprostinil s.c./inhaled iloprost plus sildenafil [125] | 13 IPAH | ↓ NYHA FC | ↓ RVES diameter | | | | | |
| | 6 toxic oil PAH | ↓ Right heart failure | | | | | | | |
| | 1 HIV-APAH | ↑ 6MWD | | | | | | | |
| Epoprostenol [126] | 41 IPAH | NA | ↓ RVED area | ↓ LVED | ↓ LVED | ↔ Pericardial effusion score | | | | | | Maximal TRV | ↓ Tei index |
| Beraprost/inhaled iloprost/iloprost i.v. plus bosentan [127] | 10 IPAH | ↑ 6MWD | | | | | | | | | | | |
| | 6 other PAH | ↑ 6MWD | | | | | | | | | | | |
isovolumic relaxation time (IVRT), the ventricular filling can be quantified by the peak filling rate and filling pattern. When diastolic function in PAH was evaluated using these indices, IVRT was found to correlate well with right ventricle mass and PVR, as well as disease severity as assessed by 6MWD, NT-proBNP level, CI and right ventricular ejection fraction, and IVRT was sensitive to afterload reduction with sildenafil [106].

The left ventricle is intimately connected to the right ventricle via the interventricular septum. Moreover, both the right and left ventricles are enclosed within a common pericardial sac occupying the same thoracic cavity. Therefore, changes in the structure and function of the right ventricle also affect the left ventricle. The MRI delayed contrast enhancement technique is used to demonstrate myocardial fibrosis with high spatial resolution. Myocardial delayed enhancement is frequently noted in right ventricular septal insertion points in PAH [107, 108]. Recent work using echocardiographic techniques in PH patients indicates that not only the right ventricle free wall and interventricular septal longitudinal shortening but also the circumferential shortening of the left ventricular lateral wall and interventricular septum and left ventricle systolic torsion are reduced [109]. With RV pressure overload, the septum flattens or even bulges to the left in early diastole. This paradoxical septal motion was classically believed to result from negative interventricular pressure gradient between left and right ventricles during diastole by studies using M-mode echocardiography and haemodynamics [110], and subsequently confirmed by cMRI [111]. Tagged MRI study indicates that this paradoxical septal motion is a result of higher pressure in the right than in the left ventricle leading to interventricular asynchrony due to a prolonged right ventricle contraction. This ventricular asynchrony impedes left ventricle diastolic filling, causing a lowered LVEDV [112, 113]. Right intraventricular dyssynchrony is also more prevalent in patients with PAH compared with controls as measured by two-dimensional strain echocardiography [114] and Doppler echocardiography [115].

### TABLE 2

| Biomarkers                      | Patients                          | Conventional end-points | Surrogate end-points |
|---------------------------------|----------------------------------|-------------------------|----------------------|
| Bosentan [128]                  | 18 CTD-APAH                      | ↔ WHO class III         | ↓ NO                |
|                                 |                                  | ↑ 6MWD                  | ↓ sCD40L             |
|                                 | Bosentan and sildenafil [118]    |                         | ↑ P-selectin         |
|                                 | 9 IPAH                           |                         | ↓ NT-proBNP          |
|                                 | 3 CTD-APAH                       |                         |                      |
|                                 | 2 CHD-APAH                       |                         |                      |
|                                 | 1 HIV-APAH                       |                         |                      |
|                                 | 26 PAH (IPAH and CTD-APAH)       | ↑ 6MWD                  | ↓ BNP                |
|                                 |                                  | ↑ CI                    |                      |

cMRI: cardiac magnetic resonance imaging; IPAH: idiopathic PAH/primary pulmonary hypertension; CTD-APAH: PAH associated with connective tissue disease; CHD-APAH: PAH associated with congenital heart disease; PPH: portopulmonary hypertension; CTEPH: chronic thromboembolic pulmonary hypertension; IP: idiopathic pulmonary fibrosis; 6MWD: 6-min walk distance; PVR: pulmonary vascular resistance; CI: cardiac index; NYHA FC: New York Heart Association functional class; NA: not applicable; WHO: World Health Organization; RV: right ventricular; RVSP: RV stroke volume; CO: cardiac output; RVEDV: RV end-diastolic volume; Ppa: mean pulmonary artery pressure; RVEF: RV ejection fraction; LV: left ventricular; LVSEI: LV systolic eccentricity index; LVEDV: LV end-diastolic volume; TRV: tricuspid regurgitation jet velocity; Ppa,syst: pulmonary artery systolic pressure; PVVTI: pulmonary valve velocity time integral; RVMPI: RV myocardial performance index; LVEDV: LV end-diastolic; RVES: RV end-systolic; RVEDD: RV end-diastolic; NO: nitric oxide; sCD40L: human soluble CD40 ligand; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro-BNP.
CONCLUSIONS
Use of various tools has provided important insights in the natural history of PAH (table 2). No single tool provides comprehensive information regarding disease progression, stability and prognosis. There is on-going progress in better approaches for the evaluation of PAH. It is important to use existing and emerging techniques judiciously with an intent to validate some of the emerging paradigms in multicentre trials [129].

SUPPORT STATEMENT
This work is supported in part by NIH-NHLBI 5R01HL104018 (H. Gupta).

STATEMENT OF INTEREST
H. Gupta has acted as a scientific consultant to Actelion, Pfizer, Bayer Healthcare, United Therapeutics and LungRX, a fee for organising education from Pfizer, funds for research from Actelion and Pfizer, and funds for a member of staff from Pfizer.

REFERENCES
1 Badesch DB, Champion HC, Gomez Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S55–S66.
2 Hatano S, Strasser T. Primary Pulmonary Hypertension. Geneva, World Health Organization, 1975.
3 Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43–S54.
4 Galié N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.
5 McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
6 Sharkey S. A Guide to Interpretation of Hemodynamic Data in the Coronary Care Unit. 1st Edn. Philadelphia, Lippincott Williams and Wilkins, 1997.
7 Howell JBL, Permutt S, Proctor DF, et al. Effect of inflation of the lung on different parts of pulmonary vascular bed. J Appl Physiol 1961; 16: 71–76.
8 Fishman AP, McClenment J, Himmelstein A, et al. Effects of acute anoxia on the circulation and respiration in patients with chronic pulmonary disease studied during the steady state. J Clin Invest 1952; 31: 770–781.
9 Buffington CW, Nystrom EU. Neither the accuracy nor the precision of thermal dilution cardiac output measurements is altered by acute tricuspid regurgitation in pigs. Anesth Analg 2004; 98: 884–890.
10 Hoeper MM, Maier R, Torgers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 535–541.
11 Levitzky M. Pulmonary Physiology. 4th Edn, New York, McGraw Hill, Inc, 1995.
12 Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546–2552.
13 Frantz RP, Benza RL, Kjellström B, et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008; 27: 780–788.
14 Karamanoglu M, McGoon M, Frantz RP, et al. Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. Chest 2007; 132: 37–43.
15 Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 1898–1907.
16 Morales-Blanxir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98: 225–234.
17 Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–3111.
18 Pepke-Zaba J, Higenbottom TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173–1174.
19 Rubin LJ, Groves BM, Reeves JT, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334–338.
20 Schrader BJ, Inbar S, Kaufmann L, et al. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19: 1060–1064.
21 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81.
22 Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension. Chest 2007; 131: 1917–1928.
23 Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780–2785.
24 Currie P, Seward J, Chan K, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1982; 6: 750–756.
25 Hindelapter AL, Willis PW, Long WA, et al. Frequency and severity of tricuspid regurgitation determined by Doppler echocardiography in primary pulmonary hypertension. Am J Cardiol 2003; 91: 1033–1037.
26 Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615–621.
27 Hachulla E, Cressin V, Guelvivin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792–3800.
28 Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 1, S40–S47.
29 Huntsman LL, Stewart DK, Barnes SR, et al. Noninvasive Doppler determination of cardiac output in man. Clinical validation. Circulation 1983; 67: 593–602.
30 Christie J, Sheldahl LM, Tristani FE, et al. Determination of stroke volume and cardiac output during exercise: comparison of two-dimensional and Doppler echocardiography, Fick oximetry, and thermodilution. Circulation 1987; 76: 539–547.
31 Nagaeuf SE, Middleton Kj, Kopehen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527–1533.
Venkatesh BA, Schiros CG, Gupta H, Roeleveld RJ, Marcus JT, Boonstra A, Belenkie I, Smith E, Tyberg J. Ventricular interaction: from bench to bedside. Ann Med 2001; 33: 236–241.

Yin FC. Ventricular wall stress. Circ Res 1987; 113: 1114–1122.

Yeo TC, Djurjadin K, Hodge D, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996; 9: 838–847.

Zang J, Poon M, et al. Pulmonary hypertension: accuracy of detection with left ventricular septal-to–free wall curvature ratio measured at cardiac MRI. Radiology 2007; 243: 63–69.

Zina J, Kuschnir P, Rius T, et al. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. Radiology 2007; 243: 70–79.

Kondo C, Caputo GR, Masui T, et al. Pulmonary hypertension: pulmonary flow quantification and flow profile analysis with velocity-encoded cine MR imaging. Radiology 1992; 183: 751–758.

Ley S, Mereles D, Puderbach M, et al. Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension. Eur Radiol 2007; 17: 1892–1897.

Laffon E, Vallet C, Bernard V, et al. A computed method for noninvasive MRI assessment of pulmonary arterial hypertension. J Appl Physiol 2004; 96: 463–468.

Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging 2005; 22: 67–72.

Devaraj A, Hansell DM. Computed tomography signs of pulmonary hypertension: old and new observations. Clin Radiol 2009; 64: 751–760.

Ng C, Wells A, Padley S. A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 1999; 14: 270–278.

Isaacs D, Hazany S, Gamst A, et al. Evaluation of the coronary sinus on chest computed tomography in patients with and without pulmonary artery hypertension. J Comput Assist Tomogr 2009; 33: 513–516.

D’Alonzo G, Barst R, Ayres S, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.

Sandoval J, Bauerle O, Palomer A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89: 1733–1744.

Sibthon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–788.

Humbert M, Sibthon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the management era. J Am Coll Cardiol 2010; 122: 156–163.

Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Circulation 2010; 122: 164–172.

Eysmann SB, Palevsky HJ, Reichek N, et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80: 353–360.

Raymond RJ, Hindelrter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214–1219.

Tei C, Djurjadin K, Hodge D, et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996; 9: 838–847.

Yeo TC, Djurjadin KS, Tei C, et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81: 1157–1161.

Kaul S, Tei C, Hopkins J, et al. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984; 107: 526–531.

Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1034–1041.

Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004; 147: 218–223.

van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250–1257.

Gan CT, Lankhaar JW, Westerhof N, et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007; 132: 1906–1912.

Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487–492.

Paciocco G, Martinez FJ, Bossone E, et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001; 17: 647–652.

Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy
for primary pulmonary hypertension. *N Engl J Med* 1996; 334: 296–301.
74 Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension. *Circulation* 2002; 106: 319–324.
75 McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. *Circulation* 2002; 106: 1477–1482.
76 Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2004; 169: 441–447.
77 Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. *Am J Cardiol* 2003; 41: 2119–2125.
78 Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. *Am J Cardiol* 2006; 97: 123–126.
79 Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* 2000; 102: 865–870.
80 Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest* 2006; 129: 1313–1321.
81 Torbicki A, Kurzyna M, Kuca P, et al. Detectable Serum Cardiac Troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. *Circulation* 2003; 108: 844–848.
82 Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. *Am J Respir Crit Care Med* 1999; 160: 487–492.
83 Roeleveeld RJ, Vonk-Noordegraaf A, Marcus JT, et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. *Chest* 2004; 125: 572–579.
84 Sniderman A, Fitchett D. Vasodilators and pulmonary arterial hypertension: the paradox of therapeutic success and clinical failure. *Int J Cardiol* 1988; 20: 173–181.
85 McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J* 2005; 25: 244–249.
86 Sagawa K, Maughan L, Suga H, et al. Cardiac Contraction and the Pressure–Volume Relationship. New York, Oxford University Press, 1988.
87 Asahol H, Sasayama S, Kameyama T. Ventriculoarterial coupling in normal and failing heart in humans. *Circ Res* 1989; 65: 483–493.
88 Burkhoff D, Sagawa K. Ventricular efficiency predicted by an analytical model. *Am J Physiol* 1986; 250: R1021–R1027.
89 O’Rourke M, Avolio A, Nichols W. Left Ventricular–Systemic Arterial Coupling in Humans and Strategies to Improve Coupling in Disease States. New York: Springer-Verlag, 1987.
90 Fourie PR, Coetzee AR, Bolliger CT. Pulmonary artery compliance: its role in right ventricular–arterial coupling. *Cardiovasc Res* 1992; 26: 839–844.
91 Kass D, Kelly R. Ventriculoarterial coupling: concepts, assumptions, and applications. *Ann Biomed Eng* 1992; 20: 41–62.
92 Brimioulle S, Wauthy P, Ewalenko P, et al. Single-beat estimation of right ventricular end-systolic pressure-volume relationship. *Am J Physiol* 2003; 284: H1625–H1630.
93 Kuehne T, Yilmaz S, Steendijk P, et al. Magnetic resonance imaging analysis of right ventricular pressure-volume loops. *Circulation* 2004; 110: 2010–2016.
94 Wauthy P, Naeije R, Brimioulle S. Left and right ventriculoarterial coupling in a patient with congenially corrected transposition. *Cardiol Young* 2005; 15: 647–649.
95 Nichols W, O’Rourke M. McDonald’s Blood Flow in Arteries. 3rd Edn. London, Edward Arnold, 1990.
96 Grant BJ, Lieber BB. Clinical significance of pulmonary arterial input impedance. *Eur Respir J* 1996; 9: 2196–2199.
97 Huez S, Brimioulle S, Naeije R, et al. Feasibility of routine pulmonary arterial impedance measurements in pulmonary hypertension. *Chest* 2004; 125: 2121–2128.
98 Haneda T, Nakajima T, Shirato K, et al. Effects of oxygen breathing on pulmonary vascular input impedance in patients with pulmonary hypertension. *Chest* 1983; 83: 520–527.
99 Laskey WK, Ferrari VA, Palevsky HI, et al. Pulmonary artery hemodynamics in primary pulmonary hypertension. *Am J Cardiol* 1993; 21: 406–412.
100 Huez S, Vachieri J-L, Unger P, et al. Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension. *Am J Cardiol* 2007; 100: 1473–1478.
101 Dambrauskaite V, Delcroix M, Claus P, et al. Regional right ventricular dysfunction in chronic pulmonary hypertension. *J Am Soc Echocardiogr* 2007; 20: 1172–1180.
102 Kittipovannoth M, Bellavita D, Chandrasekaran K, et al. Doppler myocardial imaging for early detection of right ventricular dysfunction in patients with pulmonary hypertension. *J Am Soc Echocardiogr* 2008; 21: 1035–1041.
103 Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. *Chest* 2011; 139: 1299–1309.
104 Leeuwenburgh BPJ, Steendijk P, Helbing WA, et al. Indexes of diastolic RV function: load dependence and changes after chronic RV pressure overload in lambs. *Am J Physiol* 2002; 282: H1350–H1358.
105 Stojnic B, Brecker S, Xiao H, et al. Left ventricular filling characteristics in pulmonary hypertension: a new mode of ventricular interaction. *Br Heart J* 1992; 68: 16–20.
106 Gan CT, Holverda S, Marcus JT, et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. *Chest* 2007; 132: 11–17.
107 Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. *Eur Heart J* 2005; 26: 1993–1999.
108 McCann GP, Gan CT, Beek AM, et al. Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension. *Am J Roentgenol* 2007; 188: 349–355.
109 Puwantan S, Park M, Popović ZB, et al. Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. *Circulation* 2010; 121: 259–266.
110 Tanaka H, Tci C, Nakao S, et al. Diastolic bulging of the interventricular septum toward the left ventricle. An echocardiographic manifestation of negative interventricular pressure gradient between left and right ventricles during diastole. *Circulation* 1980; 62: 558–563.
111 Marcus JT, Vonk Noordegraaf A, Roeleveeld RJ, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension. *Chest* 2001; 119: 1761–1765.
112 Marcus JT, Gan CT-J, Zwanenburg JJM, et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. *Am J Cardiol* 2008; 101: 750–757.
113 Vonk-Noordegraaf A, Marcus JT, Gan CT, et al. Interventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling. *Chest* 2005; 128: Suppl. 6, 628S–605S.
114 Kalogeropoulos AP, Georgiopoulou V, Howell S, et al. Evaluation of right intraventricular dyssynchrony by two-dimensional strain echocardiography in patients with pulmonary arterial hypertension. *J Am Soc Echocardiogr* 2008; 21: 1028–1034.
115 Schwartz DJ, Kop WJ, Park MH, et al. Evidence for early right ventricular and septal mechanical activation (interventricular dyssynchrony) in pulmonary hypertension. *Am J Cardiol* 2008; 102: 1273–1277.
116 Chin KM, Kingman M, de Lemos JA, et al. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. *Am J Cardiol* 2008; 101: 1669–1672.

117 Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. *Am J Respir Crit Care Med* 2005; 171: 1292–1297.

118 van Wolferen SA, Boonstra A, Marcus JT, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. *Heart* 2006; 92: 1860–1861.

119 Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. *J Card Fail* 2010; 16: 121–127.

120 Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* 2003; 108: 2066–2069.

121 Nath J, DeMarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. *Echocardiography* 2005; 22: 374–379.

122 Galliè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. *J Am Coll Cardiol* 2003; 41: 1380–1386.

123 Cozzi F, Montisci R, Marotta H, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. *Eur J Clin Invest* 2006; 36: 49–53.

124 Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. *Mayo Clinic Proceedings* 2003; 78: 1207–1213.

125 Ruiz MJ, Escribano P, Delgado JF, et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanooids: 2-year experience. *J Heart Lung Transplant* 2006; 25: 1353–1357.

126 Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. *Circulation* 1997; 95: 1479–1486.

127 Seyfarth H Jr, Pankau H, Hammerschmidt S, et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanooid therapy. *Chest* 2005; 128: 709–713.

128 Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. *J Rheumatol* 2006; 36: 760–767.

129 ClinicalTrials.gov. Combination Therapy in Pulmonary Arterial Hypertension (COMPASS 3). NCT00433329. http://clinicaltrials.gov/ct2/show/NCT00433329 Date last updated: January 11, 2011. Date last accessed: September 5, 2011.